1. Executive Summary (Confidence: High)

Oviva has established itself as a dominant force in the European longevity and chronic care landscape, having treated over 800,000 patients across Switzerland, the UK, Germany, France, and Poland.^[23] Founded in 2014 by Kai Eberhardt and Manuel Baumann, the organization addresses the multi-billion dollar economic and health burden of metabolic disease through a "virtual chronic care layer" that sits inside public healthcare systems.^[19] Oviva is structurally unique for its high level of clinical validation, with over 90 peer-reviewed studies supporting its methodology, and its success in achieving formal regulatory status as a "DiGA" (Digital Health Application) in Germany and a recommended provider for the NHS in the UK.^[19] With a total funding base that was significantly augmented by a $220 million Series D in late 2025, led by Kinnevik, Oviva is scaling its operations to provide population-wide productivity benefits and reduce the long-term specialty care costs associated with complex obesity.^[19]